Table 2. Comparison of baseline variables in normal glucose tolerance subjects who developed glucose intolerance and subjects who retained normal glucose tolerance in 2005.
| Worsening group | Retaining group | P‐value | |
|---|---|---|---|
| n (male/female) | 27 (27/0) | 224 (213/11) | |
| Age (years) | 51.3 ± 6.3 | 47.9 ± 8.8 | 0.0563 |
| WC (cm) | 93.5 ± 5.7 | 91.4 ± 4.9 | 0.0391 |
| BMI (kg/m2) | 27.1 ± 2.2 | 26.5 ± 2.4 | 0.2350 |
| VFA (cm2) | 140.6 ± 27.9 | 130.0 ± 23.0 | 0.0307 |
| sBP (mmHg) | 140.2 ± 13.6 | 131.3 ± 14.6 | 0.0029 |
| dBP (mmHg) | 88.1 ± 9.3 | 83.4 ± 9.9 | 0.0197 |
| TC (mg/dL) | 212.5 ± 32.9 | 214.0 ± 32.7 | 0.8211 |
| TG (mg/dL) | 218.8 ± 198.5 | 175.6 ± 101.6 | 0.0714 |
| HDLC (mg/dL) | 54.3 ± 18.1 | 52.7 ± 14.8 | 0.5959 |
| LDLC (mg/dL) | 117.3 ± 34.7 | 124.4 ± 28.6 | 0.2373 |
| UA (mg/dL) | 6.72 ± 0.93 | 6.36 ± 1.35 | 0.1891 |
| HbA1c (%) | 5.0 ± 0.4 | 4.7 ± 0.4 | 0.0014 |
| Log (APN) | 1.8 ± 0.4 (n = 25) | 1.8 ± 0.4 (n = 205) | 0.9964 |
| OGTT: PG (mg/dL) | |||
| 0 min | 98.4 ± 7.0 | 93.2 ± 6.9 | 0.0003 |
| 30 min | 167.1 ± 26.2 | 149.3 ± 27.7 | 0.0017 |
| 60 min | 172.4 ± 33.0 | 138.1 ± 33.9 | <0.0001 |
| 120 min | 114.0 ± 19.7 | 104.2 ± 19.1 | 0.0122 |
| OGTT: IRI (μU/mL) | |||
| 0 min | 7.5 ± 4.2 | 7.8 ± 4.7 | 0.7334 |
| 30 min | 44.1 ± 39.2 | 44.3 ± 26.6 | 0.9818 |
| 60 min | 50.6 ± 34.1 | 49.5 ± 33.2 | 0.8636 |
| 120 min | 35.3 ± 18.7 | 33.0 ± 21.2 | 0.5778 |
| log (I.I.) | −0.947 ± 0.907 | −0.569 ± 0.832 (n = 216) | 0.0284 |
| AUC (glucose0–120) | 294.5 ± 37.9 | 253.6 ± 41.0 | <0.0001 |
| AUC (insulin0–120) | 79.6 ± 46.2 | 77.7 ± 42.4 | 0.8261 |
| log (HOMA‐IR) | 0.478 ± 0.509 | 0.434 ± 0.578 | 0.7036 |
Date are mean ± SD. Worsening group consisted of those who showed deterioration of glucose tolerance in 2005.
Retaining group consisted of individuals who retained normal glucose tolerance (NGT) in 2005. APN, adiponectin; AUC, area under the curve; BMI, body mass index; dBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDLC, high‐density lipoprotein cholesterol; HOMA‐IR, homeostasis model of insulin resistance; I.I., insulinogenic index; IRI, insulin; LDLC, low‐density lipoprotein cholesterol; NS, not significant; OGTT, oral glucose tolerance test; PG, plasma glucose; sBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; UA, uric acid; VFA, visceral fat area; WC, waist circumference.